John Bial News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Can harmless viruses target only the cells that need treatment? Vancouver company says yes.

Search jobs 11-May-2021 Biogen and Capsigen Announce Collaboration to Discover and Develop Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders Collaboration aims to identify novel AAV capsids with enhanced properties to facilitate the development of new gene therapies for CNS and neuromuscular disorders Capsigen’s screening technology is designed to produce dose optimized, fit for purpose vectors that may have applicability across Biogen’s gene therapy pipeline Capsigen to receive a $15 million upfront payment and is eligible to rece...

Biogen, Capsigen Launch Up-to-$1.3B AAV Capsid Collaboration May 11, 2021 Share Biogen will partner with Capsigen to engineer novel adeno-associated virus (AAV) capsids for gene therapies designed to treat CNS and neuromuscular disorders, through a strategic research collaboration that could generate more than $1.3 billion for Capsigen. The companies said they will create and identify novel AAV capsids tailored to meet disease-specific transduction profiles through their collaboration, designed to combine Capsigen’s Transcription-Dependent Directed Evolution (TRADE™) platform and associat...

Biogen and Capsigen to collaborate on gene therapies Biogen will gain exclusive right for undisclosed number of CNS and neuromuscular disease targets Biogen has announced a new strategic research collaboration with Capsigen to develop novel adeno-associated virus (AAV) capsids that have the potential to deliver gene therapies for CNS and neuromuscular disorders. Under the terms of the agreement, Biogen will gain an exclusive right under Capsigen’s proprietary technology for an undisclosed number of CNS and neuromuscular disease targets. Biogen will pay Capsigen a $15m upfront payment as wel...